Oncology Institute (TOI) Competitors

SHL Telemedicine (NASDAQ:SHLT) and Oncology Institute (NASDAQ:TOI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, community ranking, earnings and institutional ownership.

Do analysts rate SHLT or TOI?

SHL Telemedicine currently has a consensus price target of $11.00, suggesting a potential upside of 113.59%. Oncology Institute has a consensus price target of $2.25, suggesting a potential upside of 85.95%. Given Oncology Institute's higher probable upside, equities analysts plainly believe SHL Telemedicine is more favorable than Oncology Institute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SHL Telemedicine	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Oncology Institute	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has stronger valuation & earnings, SHLT or TOI?

SHL Telemedicine has higher earnings, but lower revenue than Oncology Institute.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SHL Telemedicine	$57.08M	1.32	-$80K	N/A	N/A
Oncology Institute	$324.24M	0.28	-$83.07M	-$0.92	-1.32

Does the media favor SHLT or TOI?

In the previous week, SHL Telemedicine had 3 more articles in the media than Oncology Institute. MarketBeat recorded 5 mentions for SHL Telemedicine and 2 mentions for Oncology Institute. Oncology Institute's average media sentiment score of 0.98 beat SHL Telemedicine's score of -0.13 indicating that SHL Telemedicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SHL Telemedicine	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oncology Institute	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Is SHLT or TOI more profitable?

SHL Telemedicine has a net margin of 0.00% compared to SHL Telemedicine's net margin of -24.56%. Oncology Institute's return on equity of 0.00% beat SHL Telemedicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SHL Telemedicine	N/A	N/A	N/A
Oncology Institute	-24.56%	-80.46%	-28.14%

Does the MarketBeat Community believe in SHLT or TOI?

Oncology Institute received 3 more outperform votes than SHL Telemedicine when rated by MarketBeat users. However, 100.00% of users gave SHL Telemedicine an outperform vote while only 66.67% of users gave Oncology Institute an outperform vote.

Company	Underperform	Outperform
SHL Telemedicine	Outperform Votes 1 100.00%	Underperform Votes No Votes
Oncology Institute	Outperform Votes 4 66.67%	Underperform Votes 2 33.33%

Do institutionals & insiders have more ownership in SHLT or TOI?

20.1% of SHL Telemedicine shares are owned by institutional investors. Comparatively, 36.9% of Oncology Institute shares are owned by institutional investors. 13.1% of Oncology Institute shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

SHL Telemedicine beats Oncology Institute on 9 of the 13 factors compared between the two stocks.